Literature DB >> 11854769

Cannabinoids and pain.

J M Walker1, N M Strangman, S M Huang.   

Abstract

Cannabinoids have been used to treat pain for many centuries. However, only during the past several decades have rigorous scientific methods been applied to understand the mechanisms of cannabinoid action. Cannabinoid receptors were discovered in the late 1980s and have been found to mediate the effects of cannabinoids on the nervous system. Several endocannabinoids were subsequently identified. Many studies of cannabinoid analgesia in animals during the past century showed that cannabinoids block all types of pain studied. These effects were found to be due to the suppression of spinal and thalamic nociceptive neurons, independent of any actions on the motor systems. Spinal, supraspinal and peripheral sites of cannabinoid analgesia have been identified. Endocannabinoids are released upon electrical stimulation of the periaqueductal gray, and in response to inflammation in the extremities. These observations and others thus suggest that a natural function of cannabinoid receptors and their endogenous ligands is to regulate pain sensitivity. The therapeutic potential of cannabinoids remains an important topic for future investigations, with previous work suggesting utility in clinical studies of cancer and surgical pain. New modes of delivery and/or new compounds lacking the psychotropic properties of the standard cannabinoid ligands offer promise for cannabinoid therapeutics for pain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11854769     DOI: 10.1155/2001/413641

Source DB:  PubMed          Journal:  Pain Res Manag        ISSN: 1203-6765            Impact factor:   3.037


  12 in total

Review 1.  The pharmacotherapy of chronic pain: a review.

Authors:  Mary E Lynch; C Peter N Watson
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

2.  Brain Mapping-Based Model of Δ(9)-Tetrahydrocannabinol Effects on Connectivity in the Pain Matrix.

Authors:  Carmen Walter; Bruno G Oertel; Lisa Felden; Christian A Kell; Ulrike Nöth; Johannes Vermehren; Jochen Kaiser; Ralf Deichmann; Jörn Lötsch
Journal:  Neuropsychopharmacology       Date:  2015-10-30       Impact factor: 7.853

3.  Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy.

Authors:  Megan L Uhelski; Iryna A Khasabova; Donald A Simone
Journal:  J Neurophysiol       Date:  2014-12-10       Impact factor: 2.714

Review 4.  Neuromodulators for pain management in rheumatoid arthritis.

Authors:  Bethan L Richards; Samuel L Whittle; Rachelle Buchbinder
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

Review 5.  Endocannabinoid mechanisms of pain modulation.

Authors:  Andrea G Hohmann; Richard L Suplita
Journal:  AAPS J       Date:  2006-11-17       Impact factor: 4.009

6.  Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide.

Authors:  Theodore J Price; Amol Patwardhan; Armen N Akopian; Kenneth M Hargreaves; Christopher M Flores
Journal:  Br J Pharmacol       Date:  2004-03-08       Impact factor: 8.739

7.  Cannabinoids in pancreatic cancer: correlation with survival and pain.

Authors:  Christoph W Michalski; Florian E Oti; Mert Erkan; Danguole Sauliunaite; Frank Bergmann; Pal Pacher; Sandor Batkai; Michael W Müller; Nathalia A Giese; Helmut Friess; Jörg Kleeff
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

8.  Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception.

Authors:  Adrianne R Wilson; Lauren Maher; Michael M Morgan
Journal:  Neuropharmacology       Date:  2008-08-05       Impact factor: 5.250

9.  Long-term treatment with methanandamide attenuates LPS-induced periodontitis in rats.

Authors:  Cesar A Ossola; Pablo N Surkin; Antonela Pugnaloni; Claudia E Mohn; Juan C Elverdin; Javier Fernandez-Solari
Journal:  Inflamm Res       Date:  2012-05-12       Impact factor: 4.575

10.  Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2.

Authors:  Junran Xie; Dongju Xiao; Yun Xu; Jinning Zhao; Li Jiang; Xuming Hu; Yaping Zhang; Lina Yu
Journal:  Oncotarget       Date:  2016-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.